Peter Hanson

Venture Partner at Anterra Capital
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Boston, US

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • Netherlands
    • Venture Capital and Private Equity Principals
    • 1 - 100 Employee
    • Venture Partner
      • Oct 2023 - Present

      Identifying next-generation science for major therapeutic and diagnostic targets in animal health. Anterra Capital is leveraging technology to build a safe, sustainable, and resilient food system, clearing new pathways to boost animal health and quality of life, and improving consumer access to healthier, more nutritious foods. Identifying next-generation science for major therapeutic and diagnostic targets in animal health. Anterra Capital is leveraging technology to build a safe, sustainable, and resilient food system, clearing new pathways to boost animal health and quality of life, and improving consumer access to healthier, more nutritious foods.

    • Executive Consultant
      • Jun 2023 - Present

      Providing consulting on biotechnology research, development, manufacturing and business operations Providing consulting on biotechnology research, development, manufacturing and business operations

    • United States
    • Biotechnology Research
    • 1 - 100 Employee
    • Chief Operating Officer
      • Jul 2020 - Feb 2023

      eGenesis is advancing the field of transplantation to make available safe and reliable xeno organs, tissues, and cells to patients in need. This is done through gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. eGenesis is advancing the field of transplantation to make available safe and reliable xeno organs, tissues, and cells to patients in need. This is done through gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date.

    • United States
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Chief Development Operations Officer
      • Jun 2014 - Jun 2020

      Centrexion is pioneering new treatments to relieve the suffering associated with chronic pain by developing non-opioid and non-addictive therapies. Centrexion is pioneering new treatments to relieve the suffering associated with chronic pain by developing non-opioid and non-addictive therapies.

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Head, R&D and Medical Affairs, Animal Health
      • Dec 2012 - Jun 2014

      Our vision was to be recognized for consistently setting new standards in healthcare solutions that enrich the human/pet bond. Our programs included the areas of pain, oncology and medical devices. Our vision was to be recognized for consistently setting new standards in healthcare solutions that enrich the human/pet bond. Our programs included the areas of pain, oncology and medical devices.

    • Germany
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Global Head, Project & Portfolio Management
      • May 2011 - Dec 2012

      Responsible for the team of project leaders and project managers for the company's portfolio of veterinary pharmaceutical and vaccine development projects. Scope was global.

    • Head of Pharma R&D
      • Oct 2007 - May 2011

      Responsible for discovery screening, chemical development, formulation development, analytical development, and DMPK for small molecule pharmaceutical projects.

    • Executive Director, Sr Director, Director, Project Leader, Assoc Director
      • Oct 1996 - Sep 2007

      Starting as a development project leader, I led programs to global regulatory approval and launch. Over time, my leadership expanded to include other project leaders and a portfolio of pharmaceutical development projects.

    • Higher Education
    • 700 & Above Employee
    • Resident, Fellow, Lecturer
      • 1990 - 1996

      Residency in large animal surgery. Graduate work in bone biomechanics and bone transplantation/healing, leading to MS and PhD. Lectured in large animal anatomy. Residency in large animal surgery. Graduate work in bone biomechanics and bone transplantation/healing, leading to MS and PhD. Lectured in large animal anatomy.

    • Associate Veterinarian
      • 1989 - 1990

      Associate veterinarian with a split 70% equine and 30% small animal. Associate veterinarian with a split 70% equine and 30% small animal.

Education

  • University of Wisconsin-Madison
    MS / PhD / Residency, Veterinary Science and Large Animal Surgery
  • University of Minnesota
    DVM, BA-biology
  • University of Minnesota

Community

You need to have a working account to view this content. Click here to join now